Researchers Develop New Computer-based Vision Screening Test for Young Children
Easy-to-Use and accurate test can be used in schools
or pediatricians’ offices, reports new study in theJournal of AAPOS
Easy-to-Use and accurate test can be used in schools or pediatricians’ offices, reports new study in theJournal of AAPOS
eye disorders in young children are asymptomatic and may remain undetected
without testing. Since effective treatments are available for many of those
conditions, early identification and intervention are critical to prevent potentially
permanent vision problems. A new report published in the Journal of the American Association for Pediatric Ophthalmology and
(AAPOS) describes the effectiveness of a new computer-based
vision-screening test, the Jaeb Visual Acuity Screener (JVAS), which is suitable
for use in schools and pediatrician’s offices.
“Broad adoption of this tool would result in a more standardized approach to pediatric vision screening in diverse medical and community office settings,” commented lead investigator Tomohiko Yamada, OD, of the Department of Ophthalmology, Mayo Clinic, Rochester, Minnesota. “In comparison to traditional vision testing methodologies, this software-based tool provides the advantage of running on any windows-based PC in a pediatrician’s examination room—avoiding testing in distracting office hallways.”
JVAS is a computerized screening program developed by the Jaeb Center for Health Research that is designed to identify children with subnormal visual acuity in a rapid and reproducible manner. It uses a set testing algorithm to minimize subjective tester bias. It also uses age-specific visual acuity standards to provide a simple pass/fail result for four age groups (3, 4, 5 or 6, and 7 and over).
Investigators used the JVAS program to screen the vision of 175 children, ages 3 to 7, who then received a complete eye examination by an optometrist, which served as the study gold standard. The examining optometrist was kept unaware of the initial JVAS vision screening results. No children who already wore glasses, had been treated for amblyopia, or had undergone ocular surgery were included in the screening. The average screening time was 84 seconds, with a range of 23 to 357 seconds across all age groups. There were three different failure criteria evaluated: (1) failure to identify at least three of any four normal threshold letters in either eye; (2) failure to identify at least three of any five normal threshold letters in either eye; (3) failure to identify at least four of any five normal threshold letters in either eye.
Of the 65 children failing the gold standard examination, 86% failed for reduced visual acuity (56), 35% for hyperopia (23), 23 % for astigmatism (15), 11% for anisometropia (7), 9% for myopia (6), and 5% for strabismus (3), with some patients failing the gold standard for more than one reason. For the 56 children with reduced visual acuity, the primary cause assigned hierarchically was uncorrected refractive error in 31 of 56 (55%), unilateral amblyopia in 7 (13%), bilateral amblyopia in 8 (14%), and for 10 (18%) the cause of reduced visual acuity was felt to be attention-maturation without specific reason.
any screening test, high sensitivity and specificity are desirable. High
sensitivity is the ability to correctly identify those children with the target
condition(s). High specificity is the ability to correctly identify those who
do not have the target condition(s). The investigators found a sensitivity of
88% to 91% and a specificity of 73% to 86%. The proportion of false positives (screening
test failed but gold standard examination passed) was low for the JVAS, ranging
from 9% to 17%, depending on which failure criterion was used. The criterion of “failure to identify at
least three of any five normal threshold letters in either eye” gave the best
balance of sensitivity and specificity.
The testing program is offered free of charge and the investigators encourage elementary school nurses, pediatricians, and other professionals who work with children ages 3-7 years to download and use the JVAS for their vision screening needs. The program can be downloaded at www.pedig.net/JVAS.aspx.
Notes for editors
“A new computer-based pediatric vision-screening test,” by Tomohiko Yamada, OD, FAAO; Sarah R Hatt, DBO; David A Leske, MS; Pamela S Moke, MSPH; Nick L Parrucci, BSCS; J. Jeffrey Reese, BA; James B Ruben, MD; and Jonathan M Holmes, BM, BCh, DOI: http://dx.doi.org/10.1016/j.jaapos.2015.01.011. It appears in the Journal of AAPOS, Volume 19, Issue 2 (April 2015) published by Elsevier.
Full text of the article is available at to credentialed journalists upon request; contact Eileen Leahy at +1 732 238 3628 or email@example.com to obtain a copy. Journalists wishing to set up interviews with the authors should contact Bob Nellis, Mayo Clinic Research Public Affairs, at +1 507 284 5005 or Nellis.Robert@mayo.edu.
About the Journal of AAPOS (www.jaapos.org)
Journal of AAPOS presents expert information on children's eye diseases and on strabismus as it impacts all age groups. Major articles by leading experts in the field cover clinical and investigative studies, treatments, case reports, surgical techniques, descriptions of instrumentation, current concept reviews, and new diagnostic techniques. The journal is the official publication of the American Association for Pediatric Ophthalmology and Strabismus.
About the American Association for Pediatric Ophthalmology and Strabismus (www.aapos.org)
The goals of the AAPOS, the American Association for Pediatric Ophthalmology and Strabismus, are to advance the quality of children's eye care, support the training of pediatric ophthalmologists, support research activities in pediatric ophthalmology, and advance the care of adults with strabismus.
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Research Intelligence and ClinicalKey— and publishes over 2,500 journals, including The Lancet and Cell, and more than 35,000 book titles, including a number of iconic reference works. Elsevier is part of RELX Group, a world-leading provider of information and analytics for professional and business customers across industries. www.elsevier.com